Cargando…
Accelerating target deconvolution for therapeutic antibody candidates using highly parallelized genome editing
Therapeutic antibodies are transforming the treatment of cancer and autoimmune diseases. Today, a key challenge is finding antibodies against new targets. Phenotypic discovery promises to achieve this by enabling discovery of antibodies with therapeutic potential without specifying the molecular tar...
Autores principales: | Mattsson, Jenny, Ekdahl, Ludvig, Junghus, Fredrik, Ajore, Ram, Erlandsson, Eva, Niroula, Abhishek, Pertesi, Maroulio, Frendéus, Björn, Teige, Ingrid, Nilsson, Björn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904777/ https://www.ncbi.nlm.nih.gov/pubmed/33627649 http://dx.doi.org/10.1038/s41467-021-21518-4 |
Ejemplares similares
-
Essential genes shape cancer genomes through linear limitation of homozygous deletions
por: Pertesi, Maroulio, et al.
Publicado: (2019) -
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
por: Teige, Ingrid, et al.
Publicado: (2019) -
Sequence enrichment profiles enable target-agnostic antibody generation for a broad range of antigens
por: Mattsson, Jenny, et al.
Publicado: (2023) -
S100A6 is a critical regulator of hematopoietic stem cells
por: Grahn, Tan Hooi Min, et al.
Publicado: (2020) -
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
por: Wichert, Stina, et al.
Publicado: (2017)